NASDAQ:ABVX Abivax Q3 2025 Earnings Report $129.69 -2.94 (-2.22%) Closing price 04:00 PM EasternExtended Trading$99.75 -29.94 (-23.08%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Abivax EPS ResultsActual EPS-$2.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAbivax Revenue ResultsActual Revenue($4.92) millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAbivax Announcement DetailsQuarterQ3 2025Date12/15/2025TimeAfter Market ClosesConference Call DateMonday, December 15, 2025Conference Call Time11:45AM ETConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) Abivax Earnings HeadlinesAbivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis1 hour ago | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX)May 27, 2026 | theglobeandmail.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 1 at 1:00 AM | Reagan Gold Group (Ad)Abivax SA Sponsored ADR (ABVX) Gets a Buy from BarclaysMay 27, 2026 | theglobeandmail.comABIVAX Société Anonyme (ENXTPA:ABVX) Is Up 6.9% After Long-Term Obefazimod Data And Q1 Results - Has The Bull Case Changed?May 24, 2026 | finance.yahoo.comAbivax SA Sponsored ADR (ABVX) Gets a Sell from WedbushMay 23, 2026 | theglobeandmail.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxFounded in 2013 and headquartered in Paris, France, Abivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B. With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide. View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameMarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
